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Purpose: To characterize the pathogenic mutations causing mucopolysaccharidosis type I (MPS I) in two Thai patients:
one with Hurler syndrome (MPS IH), the most severe form, and the other with Scheie syndrome (MPS IS), the mildest.
Both presented with distinctive phenotype including corneal clouding.
Methods: The entire coding regions of the α-L-iduronidase (IDUA) gene were amplified by PCR and sequenced.
Functional characterization of the mutant IDUA was determined by transient transfection of the construct into COS-7
cells.
Results: Mutation analyses revealed that the MPS IH patient was homozygous for a previously reported mutation, c.
252insC, while the MPS IS patient was found to harbor a novel c.826G>A (p.E276K) mutation. The novel p.E276K
mutation was not detected in 100 unaffected ethnic-matched control chromosomes. In addition, the glutamic acid residue
at codon 276 was located at a well conserved residue. Transient transfection of the p.E276K construct revealed a significant
reduction of IDUA activity compared to that of the wild-type IDUA suggesting it as a disease-causing mutation.
Conclusions: This study reports a novel mutation, expanding the mutational spectrum for MPS I.
Mucopolysaccharidoses (MPs) are a group of inherited
lysosomal storage disorders resulting from a deficiency of
enzymes that catalyze the degradation of glycosaminoglycans
(GAGs). MPS I is considered as the prototypic lysosomal
storage  disease  of  the  MPS  group  which  is  caused  by  a
deficiency  of  lysosomal  α-L-iduronidase  (IDUA,  EC
3.2.1.76). As a result of defects inside the lysosomes, partially
degraded GAGs, heparan, and dermatan sulfate accumulate in
these organelles leading to progressive cellular dysfunction
and characteristic features of the disorder. MPS I has been
classified into three clinical phenotypes, with different levels
of severity: a severe form (Hurler syndrome; MPS IH; OMIM
607014),  an  intermediate  form  (Hurler-Scheie  syndrome;
MPS  IH/S;  OMIM  607015),  and  a  mild  form  (Scheie
syndrome; MPS IS; OMIM 607016) [1,2].
MPS I can be diagnosed biochemically by the presence
of  urinary  dermatan  sulfate  and  heparan  sulfate  and  the
significant reduction or absence of IDUA activity in patients’
leukocytes or skin fibroblasts [1]. The IDUA gene contains 14
exons encoding a 653-amino acid precursor protein [3,4]. At
least 110 different disease-causing mutations in IDUA have
been described with the majority being missense/nonsense
mutations.  The  splice-junction  alterations  and  nucleotide
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insertions/deletions have also been reported (Human Gene
Mutation  Database,  accessed  September,  2010).  The
p.W402X and p.Q70X mutations are most commonly found
in Caucasians and are accountable for as much as 70% of the
disease alleles in some European countries [5-7].
There has been only one report on Thai patients with
molecularly  confirmed  Hurler  syndrome  [8].  Here,  we
described  two  unrelated  Thai  patients  with  MPS  I  and
identified  one  recurrent  and  one  novel  mutations in IDUA.
The functional consequence of the novel missense mutation
was also further elucidated.
METHODS
Subjects:  Two  unrelated  Thai  patients  with  clinically
diagnosed MPS I were reported. Patient 1, a product of a
consanguineous marriage, with clinical features consistent
with MPS IH was diagnosed at one year of age. The clinical
findings included coarse facial features, corneal clouding,
hepatosplenomegaly, and skeletal deformities. He was noted
to have delayed development and passed away at age two from
severe respiratory infection. Patient 2 was adopted and was
diagnosed with MPS IS at the age of 29 years. The clinical
features included coarse facial features, corneal clouding and
claw hand  deformity.  The  α-L-iduronidase  activity  in
leukocytes  from  patient  2  was  measured  and  revealed  a
significant  reduction  in  enzyme  activity  (0.61  nmol/h/mg
protein). The mean of α-L-iduronidase activity in leukocytes
obtained  from  eight  unaffected  adult  Thai  controls  was
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45623.10±8.80  nmol/h/mg  protein.  Unfortunately,  leukocytes
from patient 1 were unavailable for analysis.
Mutation analysis of the IDUA gene: After informed consent,
genomic  DNA  was  extracted  from  peripheral  blood
leukocytes from patients and available parents according to
standard protocols. The entire coding regions of IDUA were
assessed  by  polymerase  chain  reaction  (PCR)  and  direct
sequencing. Most of the oligonucleotide primers were used as
previously described [9] and presented in Table 1. Exons 3–
6, 13–14, and their intron-exon boundaries were amplified
using newly designed primers (Table 1). The PCR products
were treated with ExoSAP-IT (USP Corporation, Cleveland,
OH), according to the manufacturer’s recommendations, and
sent  for  direct  sequencing  at  the  Macrogen,  Inc.  (Seoul,
Korea).  The  sequences  were  analyzed  using  Sequencher
(version 4.2; Gene Codes Corporation, Ann Arbor, MI).
For a novel missense mutation, c.826G>A (p.E276K),
PCR-RFLP analysis with the MboII restriction enzyme was
used to confirm its presence in the patient and to screen in 100
ethnic-matched  unaffected  control  chromosomes.  The
forward and reverse primers for amplification of IDUA exon
7 were used to generate a 448-bp PCR product. The mutant
PCR  product  creates  another  MboII  site,  which  allowed
detection of the mutation by agarose gel electrophoresis. As
the proband was adopted, the parental DNA was not available
for analysis.
Protein  sequence  comparison:  IDUA  orthologs  were  first
identified  through  a  BLAST  search  of  the  non-redundant
database  using  Homo  sapiens  IDUA,  accession
NP_000194.2  as  the  reference  sequence.  All  known  and
complete IDUA sequences were included from the vertebrate
lineage. These files in FASTA format were then analyzed by
ClustalX  program.version  2.0.12.  The  human  IDUA  was
aligned  with  rat  (Rattus  norvegicus;  NP_001165555.1),
mouse  (Mus  musculus;  NP_032351.1),  cow  (Bos  taurus;
XP_877410.2), chicken (Gallus gallus; NP_001026604.1),
frog  (Xenopus  laevis;  NP_001087031.1),  and  zebrafish
(Danio  rerio;  XP_001923689.1).  The  program  classified
amino acids by the variation in polarity, assessing both amino
acid class conservation and evolutionary conservation at any
given site.
Construction of plasmids and site-directed mutagenesis: The
expression  vector  wild-type  pEFNeo-IDUA  was  kindly
provided  by  Hopwood’s  laboratory.  The  mutant  IDUA
constructs  of  c.1206G>A  (p.W402X)  and  c.826G>A
(p.E276K)  were  generated  by  in  vitro  site-directed
mutagenesis  (QuickChange  site-directed  mutagenesis  kit;
Stratagene,  La  Jolla,  CA)  on  the  pEFNeo-IDUA  using
oligonucleotide  primers.  The  p.W402X  was  a  previously
described mutation in MPS IH and was used as a mutant
control. All mutant IDUA constructs were verified by direct
sequencing.
Transient transfection and enzyme assay: COS-7 cells were
grown in Dulbecco’s Modified Eagle Medium supplemented
with 10% fetal bovine serum at 37 °C and 5% CO2. COS-7
cells were transfected with the wild- type or mutant constructs
using  Lipofectamine™  2000  (Invitrogen,  Carlsbad,  CA),
according  to  the  manufacturer’s  instructions.  Cells  were
harvested  after  48  h  and  assayed  for  IDUA  activity.
TABLE 1. PRIMERS AND PCR CONDITIONS FOR IDUA MUTATION ANALYSIS.
Exon Primer name Primer sequences for PCR (5′ to 3′) Product size
(bp)
Melting temperature
(°C)
1 IDUA-Ex1F F-ACCCAACCCCTCCCAC 398 58
  IDUA-Ex1R R-AGCTTCAGAGACCGGAG    
2 IDUA-Ex2F F-GAACGTGTGTGTCAGCCG 304 62
  IDUA-Ex2R R-GCTCGGAAGACCCCTTGT    
3–4 IDUA-Ex3/4F F-TTCCAGCCTGGAGCATGGAG 516 62
  IDUA-Ex3/4R R-GTTGCACCCCTATGACGCAG    
5–6 IDUA-Ex5/6F F-TCACCTTGCACCCTCCCTCC 576 62
  IDUA-Ex5/6R R-GCTGACCCTGGTGGTGCTGA    
7 IDUA-Ex7F F-TGCGGCTGGACTACATCTC 448 62
  IDUA-Ex7R R-GCAGCATCAGAACCTGCTACT    
8 IDUA-Ex8F F-CCACCTTCCTCCCGAGAC 386 62
  IDUA-Ex8R R-GGAGCGCACTTCCTCCAG    
9–10 IDUA-Ex9F F-TCCTTCACCAAGGGGAGG 701 58
  IDUA-Ex10R R-TCCTCAGGGTTCTCCAGG    
11–12 IDUA-Ex11/12F F-GTGTGGGTGGGAGGTGGA 466 62
  IDUA-Ex11/12R R-CTTCACCCATGCGGTCAC    
13–14 IDUA-Ex13/14F F-CTGCCTGCTCCCACCTTTGHA 530 62
  IDUA-Ex13/14R R-CCCATGCTGCCCTCCCATCA    
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457Experiments  were  performed  twice  with  triplicate  per
experiment.
An assay for IDUA activity was performed using the
fluorogenic  substrate  4-methylumbellliferyl-α-L-iduronide
(Glycosynth, Cheshire, UK) as previously described [10]. The
protein concentration of the cell lysates was determined by the
Bradford assay.
RESULTS
PCR-sequencing revealed a homozygous c.252insC mutation
in patient 1 (Figure 1, left upper panel). Sequence analysis of
the parental genomic DNA confirmed that both parents were
heterozygous  for  the  c.252insC.  This  mutation  has  been
previously described to be associated with a severe phenotype
in different populations including Thai [6,8].
A novel homozygous c.826G>A mutation in exon 7 was
identified  in  patient  2.  This  was  expected  to  result  in  a
glutamic acid to lysine substitution (p.E276K) at codon 276
(Figure 1, right upper panel). No other variants were observed.
Restriction enzyme digestion of the PCR products with
MboII was used to confirm the presence of the c.826G>A
mutation in the patient 2 and its absence in 100 ethnic-matched
unaffected control chromosomes. Alignment of the IDUA
protein sequences revealed that the glutamic acid residue at
codon 276 was located at a well conserved residue (Figure 2).
The  functional  effect  of  the  novel  p.E276K  and  the
previously identified p.W402X mutations on IDUA activity
were  analyzed  by  transient  transfection  of  each  IDUA
construct into COS-7 cells. Comparing to the enzyme activity
Figure 1. Mutation analysis. The left and
right panels relate to c.252insC and c.
826G>A  (p.E276K)  mutations,
respectively.  Upper,  middle  and  left
lower panels are electropherograms of
patients, unaffected controls, and one of
the  parents,  respectively.  Each
identified mutation is indicated by an
arrow. Right lower panel showing RFLP
analysis for the c.826G>A mutation in
patient 2. MboII digested the wild-type
allele of a control into 247 and 201-bp
products.  The  c.826G>A  creates
another  cleavage  site  for  MboII
resulting in 169 and 32-bp bands. Note
that the 32-bp band is not visualized.
(M=100-bp  marker,  P=patient,
C=control, U=uncut amplified product).
The  500-bp  band  is  indicated  by  an
arrowhead.
Figure 2. Protein sequence alignment of IDUA from different species. The site of the amino acid variant found in this study is indicated in
bold red in all conserved species. Sites that are 100% conserved across all sequences are indicated by dots (.). Hs, Homo sapiens; Bt, Bos
taurus; Rn, Rattus norvegicus; Mm, Mus musculus; Gg, Gallus gallus; X1, Xenopus laevis; Dr, Danio rerio.
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the  p.E276K  and  the  p.W402X  had  reduced  activity  to
background  levels  (31.88±6.05  nmol/h/mg  protein  and
21.10±12.57 nmol/h/mg protein, respectively, Table 2).
DISCUSSION
We identified two unrelated Thai patients with MPS I. Patient
1 was found to be homozygous for the c.252insC mutation. It
has been previously described to be responsible for a severe
phenotype.  The  novel  missense  mutation,  c.826G>A
(p.E276K), was identified in patient 2 with MPS IS and caused
a significant reduction of IDUA activity.
There was only one report describing two patients with
MPS  IH  in  the  Thai  population.  Four  different  mutations
including  the  c.252insC  were  detected.  Combined  this
previous report with our findings, the c.252insC mutation is
responsible for 40% (2 out of 5 alleles), making it a possible
common  mutant  allele  in  Thai  patients  with  MPS  IH.
Continued studies for mutations in patients with MPS I will
be required for a definite conclusion. If this is proved to be the
case, it will benefit a molecular diagnosis for this population.
Our patient with MPS IS was found to carry the novel c.
826G>A (p.E276K) mutation. Due to the unavailability of her
parent’s DNA, a possibility that the other allele is deleted
making her hemizygous for the c.826G>A remains. As no
other  variants  were  observed,  the  patient  could  be  either
homozygous or hemizygous for this particular mutation.
Several lines of evidence support the pathogenicity of this
novel mutation. First, it is not found in 100 ethnic-matched
control chromosomes. Second, the glutamic acid at codon 276
is located at a well conserved residue (Figure 2). And most
importantly, when transiently transfected COS-7 cells with
the p.E276K construct, IDUA enzyme activity was reduced
to background levels. We also tested for the effect of the
p.W402X,  one  of  the  most  common  mutations  found  in
Caucasian individuals with MPS I, and revealed a significant
reduction of IDUA activity similar to previous reports [9]. Our
studies therefore suggested the p.E276K as a disease-causing
mutation.
Prediction  of  a  patient’s  clinical  phenotype  through
genetic analysis of IDUA has been complicated by the high
number  of  disease-causing  mutations  and  polymorphic
variants present in the IDUA gene. It has been hypothesized
that  a  combination  of  mutations,  polymorphisms,  genetic
background,  and  environmental  factors  contribute  to  the
clinical phenotypic spectrum [9,11,12]. Even though studies
of genotype-phenotype correlations for MPS I patients are
sometimes inconclusive, the nonsense mutations if present on
both IDUA alleles have been shown to cause a severe form of
MPS I. The c.252insC causing frameshift identified in our
patient with MPS IH has been previously reported in two
patients,  one  from  the  Netherlands  and  the  other  from
Thailand [6,8]. Both were compound heterozygotes for the c.
252insC and other nonsense mutations. Our finding of another
MPS IH patient associated with the homozygous c.252insC
mutation  further  supports  the  deleterious  effect  of  this
particular mutation on the enzyme activity.
In summary, we reported two unrelated Thai patients with
MPS I with different clinical severity who were found to carry
different mutations. Combined with a previous study in Thai
patients, the c.252insC mutation identified in our patient with
MPS  IH,  could  be  a  common  mutation  causing  Hurler
syndrome in the Thai population. We also detected a novel
missense mutation of the IDUA gene, c.826G>A (p.E276K)
causing Scheie syndrome.
Transient  transfection  studies  and  assay  for  IDUA
activity confirmed its pathogenic role. This study expands the
mutational spectrum of MPS I.
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